A fresh $1.5M in Series A funding is heading to Xeris Pharmaceuticals, Inc., a biopharmaceutical company focused on improving patient lives. The growth-oriented firm develops and commercializes advanced products across a range of therapies.

Get the full Xeris Pharmaceuticals, Inc. company profile
Access contacts, investors, buying signals & more
A fresh $1.5M in Series A funding is heading to Xeris Pharmaceuticals, Inc., a biopharmaceutical company focused on improving patient lives. The growth-oriented firm develops and commercializes advanced products across a range of therapies.
Portfolio company of VentureWell

Doorstep
Doorstep provides hyper-precise indoor tracking, giving delivery platforms real-time visibility into the most crucial step of last-mile operations鈥攖he drop-off. Our lightweight SDK uses proprietary algorithms and sensor fusion to detect entrances, elevators, floors, and drop-offs, all while drivers deliver as usual. This level of precision reduces service costs, eliminates disputes, prevents fraudulent refund claims, and boosts efficiency by proving the exact drop-off location. Headquartered in New York, Doorstep powers deliveries at scale with some of the world鈥檚 leading platforms and carriers.
$8.0M Seed
today

Kindo
Kindo is the AI control platform for enterprises, running on-prem, self-managed, or in our SOC 2 cloud. Teams connect the tools they already use, then build agents or work in chat with the models they choose, while every action runs through controls the business sets. Security, IT, finance, and compliance leaders use Kindo to see what AI is doing and what it costs, set permissions and budgets, step in to fix any agent, and keep a full audit trail, so the company can put AI to work without losing control of its data, risk, or spend.
Largest funding rounds in Biotechnology on Signalbase right now.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() Shockwave Medical United States | Unknown | $13.1B | 2y ago |
| 2 | ![]() NeuroEM Therapeutics United States | Unknown |
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() Orakl Oncology France | Series a | $34.0M | 3d ago |
| 2 | ![]() Mount Thor, Inc. | Series a | $45.0M | 3d ago |
$30.0M Unknown
3 days ago
| $7.2B |
| 2y ago |
| 3 | ![]() Illumina United States | Unknown | $7.1B | 2y ago |
| 4 | ![]() GRAIL United States | Unknown | $7.1B | 2y ago |
| 5 | ![]() RemeGen Biosciences United States | Grant | $5.6B | 10mo ago |
| 3 |
![]() luminal |
| Series a |
| $25.0M |
| 3d ago |
| 4 | ![]() Tristar AI United States | Series a | $12.4M | 3d ago |
| 5 | ![]() Hatz AI United States | Series a | $24.0M | 3d ago |
Contacts, investors, buying intent signals & tech stack.
Trusted by 200+ sales teams
See who invested in Xeris Pharmaceuticals, Inc. and reach their contacts directly.
Start free trialCarissa H.
Senior Director, Marketing Strategy
Mike M.
Regional Business Director, Rare Disease (Endocrinology)
Unlock 8 more key decision-makers at Xeris Pharmaceuticals, Inc. with verified emails and LinkedIn.
Start free trial
TuDOC
Recently received

Shyld AI
Recently received

Cardia, Inc.
Recently received